Entering text into the input field will update the search result below

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2020 Results - Earnings Call Transcript

May 05, 2020 10:24 PM ETIovance Biotherapeutics, Inc. (IOVA)
SA Transcripts profile picture
SA Transcripts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET

Company Participants

Sara Pellegrino - Vice President Investor & Public Relations

Maria Fardis - President & Chief Executive Officer

Friedrich Finckenstein - Chief Medical Officer

Tim Morris - Chief Financial Officer

Conference Call Participants

Mara Goldstein - Mizuho

Peter Lawson - Barclays

Jim Birchenough - Wells Fargo

Joe Catanzaro - Piper Sandler

Madhu Kumar - Baird

Boris Peaker - Cowen

Mark Breidenbach - Oppenheimer

Ben Burnett - Stifel

Reni Benjamin - JMP Securities

Joe Pantginis - H.C. Wainwright

Geulah Livshits - Chardan

Biren Amin - Jefferies


Good afternoon, and welcome to Iovance First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that this call consists of a recording of prepared remarks followed by a live question-and-answer session.

Now, I would like to turn the call over to Sara Pellegrino, Vice President Investor and Public Relations at Iovance. Please go ahead.

Sara Pellegrino

Thank you, Howard. Good afternoon, everyone and thank you for joining us. Speaking on the call today, we have Maria Fardis, our President and Chief Executive Officer; Friedrich Finckenstein, our Chief Medical Officer; and Tim Morris, Chief Financial Officer.

This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the first quarter ended on March 31, 2020 as well as a corporate update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans, pre-commercial activities, clinical trial, plans and results potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, collaboration, impact of COVID-19 and future updates.

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.